Published in J Clin Oncol on June 01, 2007
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas (2010) 2.84
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2009) 2.51
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) (2009) 1.92
Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res (2015) 1.91
Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging (2011) 1.89
Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst (2012) 1.78
A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging (2013) 1.63
Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer (2011) 1.49
Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer (2009) 1.48
A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol (2008) 1.39
Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol (2012) 1.36
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2012) 1.28
Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf) (2008) 1.25
Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab (2010) 1.24
Sporadic paraganglioma. World J Surg (2008) 1.22
Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med (2009) 1.21
Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab (2011) 1.19
Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res (2008) 1.17
Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med (2008) 1.12
Metastatic paraganglioma. Semin Oncol (2010) 1.12
Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab (2013) 1.08
Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions. Clin Endocrinol (Oxf) (2013) 1.08
Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev (2014) 1.07
Ectopic acromegaly due to growth hormone releasing hormone. Endocrine (2012) 1.05
False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer (2012) 1.05
Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist (2013) 0.97
Phaeochromocytoma: a catecholamine and oxidative stress disorder. Endocr Regul (2011) 0.97
Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? Eur J Nucl Med Mol Imaging (2008) 0.94
Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res (2012) 0.94
Update on pediatric pheochromocytoma. Pediatr Nephrol (2008) 0.92
Pheochromocytoma and paraganglioma. Prog Brain Res (2010) 0.91
Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma. Clin Cancer Res (2013) 0.90
Pheochromocytoma - update on disease management. Ther Adv Endocrinol Metab (2012) 0.89
Molecular imaging of neuroendocrine tumors. Semin Oncol (2010) 0.89
Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med (2011) 0.87
Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg (2011) 0.83
Familial pheochromocytomas and paragangliomas. Mol Cell Endocrinol (2013) 0.83
Recurrent urinary bladder paraganglioma. Adv Urol (2010) 0.83
Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. Semin Nucl Med (2013) 0.82
Renaissance of (18)F-FDG positron emission tomography in the imaging of pheochromocytoma/paraganglioma. J Clin Endocrinol Metab (2014) 0.82
Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma. Endocrine (2009) 0.81
Diagnostic Performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma. Nucl Med Mol Imaging (2015) 0.81
Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. Surgery (2011) 0.81
Paraganglioma syndrome type 1 in a patient with Carney-Stratakis syndrome. Nat Rev Endocrinol (2010) 0.80
Mitochondrial Deficiencies in the Predisposition to Paraganglioma. Metabolites (2017) 0.79
Determination of the unmetabolised (18)F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. Med Biol Eng Comput (2015) 0.79
PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2016) 0.79
Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer (2016) 0.77
Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol (2012) 0.77
Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-up. Eur J Nucl Med Mol Imaging (2015) 0.76
Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol (2015) 0.75
Findings on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in a patient with malignant pheochromocytoma. Mol Imaging Radionucl Ther (2011) 0.75
Endocrine hypertension: An overview on the current etiopathogenesis and management options. World J Hypertens (2015) 0.75
An unusual case of gastrointestinal bleeding. Case Rep Pediatr (2012) 0.75
Rapidly Growing Chest Wall Mass in a Case of Sporadic Metastatic Paraganglioma: Imaging With 4 Different PET Radiopharmaceuticals. Clin Nucl Med (2016) 0.75
Laparoscopic cortical sparing adrenalectomy for pediatric bilateral pheochromocytoma: anesthetic management. Anesth Pain Med (2014) 0.75
Diagnosis: imaging of pheochromocytomas and paragangliomas. Nat Rev Endocrinol (2010) 0.75
(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging (2016) 0.75
Screening: Correlation of genotype and phenotype in paraganglioma. Nat Rev Endocrinol (2009) 0.75
Update on Modern Management of Pheochromocytoma and Paraganglioma. Endocrinol Metab (Seoul) (2017) 0.75
Marker-Negative Pheochromocytoma Associated with Inferior Vena Cava Thrombosis. Case Rep Urol (2017) 0.75
Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. Langenbecks Arch Surg (2017) 0.75
Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. J Nucl Med (2017) 0.75
SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol (2017) 0.75
Novel germline SDHD mutation: diagnosis and implications to the patient. Fam Cancer (2011) 0.75
A case of a metastatic SDHA mutated paraganglioma re-presenting twenty-three years after initial surgery. Endocr Relat Cancer (2017) 0.75
Phaeochromocytoma. Lancet (2005) 8.73
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab (2005) 3.32
Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab (2007) 3.25
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Tumor-induced osteomalacia. Endocr Relat Cancer (2011) 3.13
Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf) (2013) 3.12
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas (2010) 2.84
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension (2013) 2.72
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.72
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med (2007) 2.68
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet (2007) 2.64
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2009) 2.51
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol (2010) 2.42
Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab (2007) 2.41
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Hypertension (2007) 2.33
Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. Arch Pathol Lab Med (2014) 2.31
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. Eur J Endocrinol (2014) 2.13
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nucl Med Commun (2013) 2.12
Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med (2009) 2.12
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov (2013) 2.11
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood (2010) 2.09
Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab (2003) 2.08
High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab (2006) 2.04
Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab (2004) 2.00
Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. Cell Metab (2009) 1.98
New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) (2009) 1.92
The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med (2007) 1.91
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther (2003) 1.87
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J (2005) 1.80
Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst (2012) 1.78
Cardiovascular manifestations of phaeochromocytoma. J Hypertens (2011) 1.74
Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab (2003) 1.70
Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev (2004) 1.69
Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol (2010) 1.67
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation (2009) 1.63
Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens (2007) 1.61
Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab (2004) 1.60
Sympathoinhibition by atorvastatin in hypertensive patients. Circ J (2010) 1.58
Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. J Clin Endocrinol Metab (2002) 1.57
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res (2006) 1.57
A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol (2004) 1.56
Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab (2005) 1.55
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer (2008) 1.54
Effects of hypo- and hyperthyroidism on noradrenergic activity and glycerol concentrations in human subcutaneous abdominal adipose tissue assessed with microdialysis. J Clin Endocrinol Metab (2003) 1.54
Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem (2005) 1.52
Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab (2007) 1.51